Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
4 clinical trials · Condition
◉ Watch Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
| Record | Firm | Date |
|---|---|---|
| Cerliponase Alfa Observational Study in the US (NCT04476862) | BioMarin Pharmaceutical | 2020-08-19 |
| A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease (NCT02678689) | BioMarin Pharmaceutical | 2016-01-22 |
| An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease (NCT02485899) | BioMarin Pharmaceutical | 2015-02-01 |
| A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease (NCT01907087) | BioMarin Pharmaceutical | 2013-09-01 |
Track Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 automatically
Every clearance here is in the API, with alerts when new ones post.